ONC.TO - Oncolytics Biotech Inc.
| Previous Close | 2.0200 |
| Open | 2.0300 |
| Bid | 2.0300 x 0 |
| Ask | 2.0700 x 0 |
| Day's Range | 1.9900 - 2.1300 |
| 52 Week Range | 0.4800 - 7.8400 |
| Volume | 140,475 |
| Avg. Volume | 351,309 |
| Market Cap | 76.619M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4960 |
| Earnings Date | Mar. 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Baystreet
Stocks in play: Oncolytics Biotech Inc.
Announced positive clinical data published in a peer-reviewed journal highlighting that the combination ...
- CNW Group
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
- Thomson Reuters StreetEvents
Edited Transcript of ONC.TO earnings conference call or presentation 5-Mar-20 10:00pm GMT
Q4 2019 Oncolytics Biotech Inc Earnings Call
- CNW Group
IIROC Trade Resumption - ONC
TORONTO , March 24, 2020 /CNW/ - Trading resumes in: Company: Oncolytics Biotech Inc. TSX Symbol: ONC Resumption (ET): 02:26:07 PM IIROC can make a decision to impose a temporary suspension (halt) of trading ...
CNW GroupOncolytics Biotech® Announces Favourable AWARE-1 Safety Update
SAN DIEGO, California and CALGARY, Alberta , March 24, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1. The Committee also approved an amendment of the study to reduce the dose of Tecentriq to be consistent with the currently approved breast cancer dose of 840mg. The study will continue to enroll patients and the Safety Committee will meet again for an additional pre-planned meeting.
CNW GroupOncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, March 5, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY - News) (TSX:ONC.TO - News), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2019. "As we implemented our focused clinical development and investor relations strategies during 2019, our market valuation and trading volume experienced significant increases," said Kirk Look, Chief Financial Officer at Oncolytics. "During 2019, we successfully delivered on our strategy to engage pharma as we laid the groundwork for a catalyst rich 2020 and 2021," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.
- Zacks
Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
- CNW Group
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta , Feb. 28, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday , March 5, 2020 following release of its fourth quarter and year end 2019 financial results. Overseas callers should contact investor relations for the toll-free dial information for their country. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.
